TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9329979

Group type: EXPERIMENTAL
Intervention: Human recombinant growth hormone (hrGH, 6 mg/d for 2 wk)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human recombinant growth hormone (hrGH)
Number of subjects: 0
Study: 8492725

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 60 g arginine hydrochloride in 200 mL saline
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intravenous infusion of hydrocortisone combined with 200 mL saline
Number of subjects: 5
Study: 2874824

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31441379

Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sildenafil 100 mg
Number of subjects: 160
Study: 29744791

Group type: EXPERIMENTAL
Intervention: Olanzapine at 5 mg/day from day 1 to 5 during the second course of chemotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard antiemetic therapy without olanzapine)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Olanzapine group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 27866129

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 280
Study: 25051098

Group type: EXPERIMENTAL
Intervention: Cervista HPV HR test
Number of subjects: 900

Group type: COMPARATOR
Intervention: Hybrid Capture 2 (HC2) test
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Cervista HPV HR test with cut-off at 5.0
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Cervista HPV HR test with cut-off at 1.93
Number of subjects: 900
Study: 22797645

Group type: EXPERIMENTAL
Intervention: 420-mg silymarin
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 700-mg silymarin
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 20368561

Group type: EXPERIMENTAL
Intervention: Bortezomib, melphalan, and prednisone (VMP)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Melphalan and prednisone (MP)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Subsequent thalidomide-based therapies
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Subsequent lenalidomide-based therapies
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Subsequent bortezomib-based therapy
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Subsequent therapy (VMP)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Subsequent therapy (MP)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Adverse events during cycles 1 to 4 (VMP)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Adverse events during cycles 5 to 9 (VMP)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Peripheral neuropathy events (VMP)
Number of subjects: 682
Study: 18216062

Group type: EXPERIMENTAL
Intervention: Patient-centred education (PCE)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard patient education (SPE)
Number of subjects: 146
Study: 15980684

Group type: EXPERIMENTAL
Intervention: ABC/3TC/ZDV+EFV
Number of subjects: 448

Group type: COMPARATOR
Intervention: ABC/3TC/ZDV
Number of subjects: 448
Study: 12455305

Group type: EXPERIMENTAL
Intervention: Lidocaine patches applied every 24 hours (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine patches applied every 12 hours (group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine patches (both groups)
Number of subjects: 20
Study: 10476515

Group type: EXPERIMENTAL
Intervention: ECCE (extracapsular cataract extraction)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 34
Study: 8960841

Group type: EXPERIMENTAL
Intervention: Subcutaneous GLP-1 [7-36 amide] (1.5 nmol/kg body weight)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subcutaneous GLP-1 [7-36 amide] (single injection 30 min before a meal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subcutaneous GLP-1 [7-36 amide]
Number of subjects: 24
Study: 1672843

Group type: EXPERIMENTAL
Intervention: 60 mg slow-release isosorbide-5-mononitrate (IS-5-MN) after a 7-day therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 60 mg slow-release isosorbide-5-mononitrate (IS-5-MN) after both short- and long-term therapy
Number of subjects: 20
Study: 7050302

Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 30387144

Group type: EXPERIMENTAL
Intervention: 2 years of high-intensity exercise training (n=34)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control/yoga group (n=27)
Number of subjects: 61
Study: 29395880

Group type: EXPERIMENTAL
Intervention: Kids CafÃ© Program nutrition education intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 120
Study: 27591761

Group type: EXPERIMENTAL
Intervention: Participant-selected music characteristics
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Post-intervention interviews
Number of subjects: 27
Study: 24393781

Group type: EXPERIMENTAL
Intervention: Robotic locomotor training plus overground therapy (LKOGT) for 60 minutes, 5 days per week for 8 weeks.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional overground training (OGT) for 60 minutes, 5 days per week for 8 weeks.
Number of subjects: 88
Study: 22990398

Group type: EXPERIMENTAL
Intervention: Bio-cellulose dressing (BWD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-adherent dressing (control)
Number of subjects: 48
Study: 20071293

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy with gemcitabine and cisplatin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intravesical instillation with epirubicin
Number of subjects: 52
Study: 17986290

Group type: EXPERIMENTAL
Intervention: Pseudoexfoliation (PEX) syndrome
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) in PEX eyes
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Open-angle glaucoma (OAG) prevalence
Number of subjects: 339
Study: 15589440

Group type: EXPERIMENTAL
Intervention: Comprehensive spa therapy program for 21 days
Number of subjects: 50
Study: 12511211

Group type: EXPERIMENTAL
Intervention: Delayed condom use
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Condom slippage and/or breakage
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Predictors of delayed condom use
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Predictors of condom slippage and/or breakage
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Frequency of condom use
Number of subjects: 779
Study: 9798817

Group type: EXPERIMENTAL
Intervention: Special intervention providers trained in a brief alcohol-counseling intervention with office support system.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Special intervention providers trained in a brief alcohol-counseling intervention.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual care providers.
Number of subjects: 29
Study: 7649598

Group type: EXPERIMENTAL
Intervention: Aminophylline (AMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium valproate (SV)
Number of subjects: 0
Study: 2549535

Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 263816

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31480097

Group type: EXPERIMENTAL
Intervention: Echidna pin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Knowles pin
Number of subjects: 28
Study: 27780709

Group type: EXPERIMENTAL
Intervention: Postoperative coffee consumption (3 times daily)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Routine postoperative care without coffee consumption (Control)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 25572773

Group type: EXPERIMENTAL
Intervention: Higher protein group (HP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower protein group (LP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breastfed infants (observational group)
Number of subjects: 0
Study: 22488012

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (PRP and Control)
Number of subjects: 40
Study: 21392609

Group type: EXPERIMENTAL
Intervention: Extended-release niacin
Number of subjects: 3414

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 3414
Study: 19673939

Group type: EXPERIMENTAL
Intervention: 80 mg/day atorvastatin
Number of subjects: 166

Group type: COMPARATOR
Intervention: 20 mg/day atorvastatin
Number of subjects: 166
Study: 17955648

Group type: EXPERIMENTAL
Intervention: Acupuncture plus TCM medication
Number of subjects: 61

Group type: COMPARATOR
Intervention: TCM medication alone
Number of subjects: 61
Study: 16096518

Group type: EXPERIMENTAL
Intervention: Risperidone (0.01-0.06 mg/kg/day)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 11948054

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 10
Study: 9793283

Group type: EXPERIMENTAL
Intervention: Cavity wall treatments with copalite varnish or silver suspension
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Conventional alloy
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: High copper alloy
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: 90-degree cavosurface angle combined with cavity wall finish
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Operator and type of restoration (MO/DO vs MOD)
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Overall treatment modalities
Number of subjects: 1117
Study: 7814851

Group type: EXPERIMENTAL
Intervention: Cyclosporin (10 mg/kg twice a day) for 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporin (10 mg/kg twice a day) and Indomethacin (50 mg twice a day) for 4 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 0
Study: 2799763

Group type: EXPERIMENTAL
Intervention: PAI-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAI-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protease-nexin I
Number of subjects: 0
Study: 31913254

Group type: EXPERIMENTAL
Intervention: Multi-Ingredient Preworkout Supplement (MIPS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 17
Study: 31172734

Group type: EXPERIMENTAL
Intervention: Tai chi group (56 patients, mean age 71.61±7.97 years) practiced a 6-month Tai chi program, two times a week, plus standard care
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (42 patients, mean age 69.71±8.61 years) practiced usual care
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Tai chi group
Number of subjects: 98
Study: 28585746

Group type: EXPERIMENTAL
Intervention: AS cognitive concerns intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Repeated contact control
Number of subjects: 63
Study: 26239831

Group type: EXPERIMENTAL
Intervention: High-protein breakfast (HP) - 35 g protein, 1,464 kJ
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Normal-protein breakfast (NP) - 13 g protein, 1,464 kJ
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (CON) - skipped breakfast
Number of subjects: 57
Study: 23744697

Group type: EXPERIMENTAL
Intervention: Neuromelanin MRI
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: (123)I-metaiodobenzylguanidine scintigraphy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Neuromelanin MRI and (123)I-metaiodobenzylguanidine scintigraphy
Number of subjects: 70
Study: 21439726

Group type: EXPERIMENTAL
Intervention: Tailored education and coaching (TEC)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 265
Study: 19406576

Group type: EXPERIMENTAL
Intervention: Tailored Barriers Intervention (TBI)
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Assessment‐alone
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1256
Study: 15290660

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg twice daily
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 10090436

Group type: EXPERIMENTAL
Intervention: Oxaprozin 1200 mg QD
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Nabumetone 1500 mg QD
Number of subjects: 679

Group type: COMPARATOR
Intervention: Nabumetone 1000 mg QD
Number of subjects: 679
Study: 7586110

Group type: EXPERIMENTAL
Intervention: 26G Atraucan needle
Number of subjects: 96

Group type: COMPARATOR
Intervention: 25G Whitacre needle
Number of subjects: 96
Study: 2073296

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg daily
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Aspirin 1,200 mg daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 7377748

Group type: EXPERIMENTAL
Intervention: Combination of sulfadiazine (SD) 250 mg + trimethoprim (TMP) 160 mg, given twice daily for one week.
Number of subjects: 85

Group type: COMPARATOR
Intervention: Combination of sulfamethoxazole (SM) 800 mg + trimethoprim (TMP) 160 mg, given twice daily for one week.
Number of subjects: 85
Study: 30994846

Group type: EXPERIMENTAL
Intervention: Virtual reality application
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 172
Study: 28408001

Group type: EXPERIMENTAL
Intervention: Skin Awareness Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study: 25690840

Group type: EXPERIMENTAL
Intervention: Prophylactic swallowing exercises
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 44
Study: 23623452

Group type: EXPERIMENTAL
Intervention: Subjective sleep difficulty
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Difficulty maintaining sleep
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Frequent nightmares
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Polysomnographic %REM-sleep
Number of subjects: 693
Study: 21542988

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at an initial dose of 10 ppm
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at a subsequent dose of 20 ppm
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no iNO)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) treated group
Number of subjects: 200
Study: 19758357

Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg b.i.d. for 4 weeks then 10 microg b.i.d.)
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Glimepiride (1 mg/day titrated to maximum dose)
Number of subjects: 1039
Study: 18176139

Group type: EXPERIMENTAL
Intervention: Western medicine therapy (WM) including diclofenac extended action tablets, methotrexate, and sulfasalazine
Number of subjects: 396

Group type: COMPARATOR
Intervention: Traditional Chinese medicine therapy (TCM) including Glucosidorum Tripterygll Totorum tablets and Yishen Juanbi tablets
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Western medicine therapy (WM)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Traditional Chinese medicine therapy (TCM)
Number of subjects: 396
Study: 15170148

Group type: EXPERIMENTAL
Intervention: Helical CT imaging
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: CT from university hospitals
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Panel assessment of CT imaging
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Post-chemotherapy assessment
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Recommendation for additional radiotherapy
Number of subjects: 371
Study: 11817797

Group type: EXPERIMENTAL
Intervention: Resin modified GIC (Fuji II LC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 0
Study: 9548155

Group type: EXPERIMENTAL
Intervention: Recombinant human FSH administered before the onset of the menstrual period (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (FSH administered in the early follicular phase after the onset of menses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 7988063

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0
Study: 30355813

Group type: EXPERIMENTAL
Intervention: Metal post group (MP)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fiber post group (FP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No post group (NP)
Number of subjects: 22
Study: 27926462

Group type: EXPERIMENTAL
Intervention: Fatty acid supplementation
Number of subjects: 296
Study: 25193002

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 59
Study: 23736351

Group type: EXPERIMENTAL
Intervention: HARP
Number of subjects: 168

Group type: COMPARATOR
Intervention: LDN
Number of subjects: 168
Study: 19727002

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (10^10 colony forming units/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactobacillus plantarum 299v and Placebo
Number of subjects: 0
Study: 19210650

Group type: EXPERIMENTAL
Intervention: Tiotropium, 18 microg once daily
Number of subjects: 78

Group type: COMPARATOR
Intervention: Salmeterol (50 microg) plus Fluticasone (200 microg), twice daily
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Salmeterol plus Fluticasone
Number of subjects: 78
Study: 17086357

Group type: EXPERIMENTAL
Intervention: Detection of Survivin-expressing circulating cancer cells
Number of subjects: 67

Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Positive Survivin-expression
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Negative Survivin-expression
Number of subjects: 67
Study: 15605005

Group type: EXPERIMENTAL
Intervention: Epinephrine injection plus bipolar probe coagulation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Bipolar probe coagulation alone
Number of subjects: 114
Study: 11734581

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (4 glasses of red wine, beer, spirits)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beer and spirits
Number of subjects: 11

Group type: COMPARATOR
Intervention: Carbonated mineral water (control)
Number of subjects: 11
Study: 9227341

Group type: EXPERIMENTAL
Intervention: Four-view radiography and corresponding histological examination
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single-view specimen radiography and arbitrary histological sectioning
Number of subjects: 40
Study: 7963068

Group type: EXPERIMENTAL
Intervention: Comorbid anxiety disorders
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Comorbid substance abuse/dependence
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Severity and duration of an index episode of major depression
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Comorbid Axis I lifetime diagnoses
Number of subjects: 116
Study: 3115354

Group type: COMPARATOR
Intervention: 20 per cent Lipofundin S (LCT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lipofundin 10 per cent MCT/10 per cent LCT
Number of subjects: 60
Study: 29509295

Group type: EXPERIMENTAL
Intervention: Belatacept more intense (MI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belatacept less intense (LI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Belatacept vs Cyclosporine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belatacept-based immunosuppression
Number of subjects: 0
Study: 27448663

Group type: EXPERIMENTAL
Intervention: Intervention Group (rewards, feedback, behaviour change techniques)
Number of subjects: 776

Group type: COMPARATOR
Intervention: Control Group (waiting list control)
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Intervention Group
Number of subjects: 776
Study: 24762631

Group type: EXPERIMENTAL
Intervention: Colonoscopy administration of fecal microbiota transplant (FMT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nasogastric tube (NGT) administration of fecal microbiota transplant (FMT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall cure rate after retreatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Daily number of bowel movements
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-reported health score
Number of subjects: 20
Study: 24621933

Group type: EXPERIMENTAL
Intervention: Amlodipine (target dose: 10 mg/d)
Number of subjects: 1654

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1654

Group type: EXPERIMENTAL
Intervention: Combined results from both trials (including earlier study)
Number of subjects: 1654

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1654
Study: 20148263

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of MMRV vaccine
Number of subjects: 328

Group type: COMPARATOR
Intervention: Subcutaneous administration of MMRV vaccine
Number of subjects: 328
Study: 18266664

Group type: EXPERIMENTAL
Intervention: Current use of antipsychotics
Number of subjects: 22944

Group type: EXPERIMENTAL
Intervention: Current use of antipsychotics (first week after initiation)
Number of subjects: 22944

Group type: EXPERIMENTAL
Intervention: Current use of atypical antipsychotics
Number of subjects: 22944

Group type: EXPERIMENTAL
Intervention: Current use of conventional antipsychotics
Number of subjects: 22944